Medtronic (MDT) Competitors $89.26 -0.48 (-0.53%) Closing price 07/15/2025 03:59 PM EasternExtended Trading$89.27 +0.02 (+0.02%) As of 08:35 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MDT vs. DXCM, ISRG, ABT, JNJ, NVST, SYK, TMO, BSX, BDX, and EWShould you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include DexCom (DXCM), Intuitive Surgical (ISRG), Abbott Laboratories (ABT), Johnson & Johnson (JNJ), Envista (NVST), Stryker (SYK), Thermo Fisher Scientific (TMO), Boston Scientific (BSX), Becton, Dickinson and Company (BDX), and Edwards Lifesciences (EW). These companies are all part of the "medical" sector. Medtronic vs. Its Competitors DexCom Intuitive Surgical Abbott Laboratories Johnson & Johnson Envista Stryker Thermo Fisher Scientific Boston Scientific Becton, Dickinson and Company Edwards Lifesciences DexCom (NASDAQ:DXCM) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Do analysts recommend DXCM or MDT? DexCom presently has a consensus target price of $98.85, suggesting a potential upside of 16.60%. Medtronic has a consensus target price of $98.06, suggesting a potential upside of 9.87%. Given DexCom's stronger consensus rating and higher probable upside, research analysts clearly believe DexCom is more favorable than Medtronic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DexCom 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.95Medtronic 0 Sell rating(s) 11 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.59 Does the media prefer DXCM or MDT? In the previous week, Medtronic had 35 more articles in the media than DexCom. MarketBeat recorded 55 mentions for Medtronic and 20 mentions for DexCom. DexCom's average media sentiment score of 1.44 beat Medtronic's score of 1.08 indicating that DexCom is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DexCom 15 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medtronic 42 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is DXCM or MDT more profitable? Medtronic has a net margin of 13.90% compared to DexCom's net margin of 12.90%. DexCom's return on equity of 30.05% beat Medtronic's return on equity.Company Net Margins Return on Equity Return on Assets DexCom12.90% 30.05% 10.00% Medtronic 13.90%14.54%7.83% Which has more volatility & risk, DXCM or MDT? DexCom has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Do insiders and institutionals hold more shares of DXCM or MDT? 97.8% of DexCom shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.3% of DexCom shares are held by insiders. Comparatively, 0.2% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, DXCM or MDT? Medtronic has higher revenue and earnings than DexCom. Medtronic is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDexCom$4.03B8.24$576.20M$1.3463.27Medtronic$33.54B3.41$4.66B$3.6224.66 SummaryDexCom beats Medtronic on 12 of the 17 factors compared between the two stocks. Get Medtronic News Delivered to You Automatically Sign up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDT vs. The Competition Export to ExcelMetricMedtronicMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$115.08B$10.37B$5.61B$20.82BDividend Yield3.17%2.09%4.23%3.65%P/E Ratio24.6616.6928.5427.17Price / Sales3.4128.91430.1147.97Price / Cash11.5822.6736.0222.28Price / Book2.373.598.144.56Net Income$4.66B$233.40M$3.24B$995.22M7 Day Performance0.15%-3.21%0.17%-1.16%1 Month Performance1.52%1.23%5.95%3.18%1 Year Performance14.27%-19.76%26.22%6.83% Medtronic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDTMedtronic4.6257 of 5 stars$89.26-0.5%$98.06+9.9%+15.7%$115.08B$33.54B24.6695,000Positive NewsAnalyst ForecastAnalyst RevisionDXCMDexCom4.7857 of 5 stars$85.20+2.2%$98.50+15.6%-25.0%$33.39B$4.15B63.5410,300Positive NewsAnalyst ForecastISRGIntuitive Surgical4.6536 of 5 stars$519.40+1.4%$592.86+14.1%+17.1%$186.16B$8.35B76.1615,638Positive NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionABTAbbott Laboratories4.9474 of 5 stars$132.55+0.4%$143.11+8.0%+27.6%$230.62B$42.34B17.19114,000Trending NewsUpcoming EarningsAnalyst ForecastJNJJohnson & Johnson4.9391 of 5 stars$156.57-0.2%$171.00+9.2%+4.1%$376.71B$89.33B17.42138,100Trending NewsNVSTEnvista3.3571 of 5 stars$20.08-0.6%$20.23+0.7%+24.2%$3.41B$2.51B-3.0812,300Positive NewsAnalyst RevisionSYKStryker4.4474 of 5 stars$392.29+0.7%$428.55+9.2%+18.9%$149.88B$22.60B53.0653,000Positive NewsAnalyst ForecastTMOThermo Fisher Scientific4.9917 of 5 stars$426.69-1.9%$600.30+40.7%-23.1%$161.07B$42.90B25.03125,000Positive NewsUpcoming EarningsDividend AnnouncementBSXBoston Scientific4.6143 of 5 stars$104.88+1.6%$116.09+10.7%+32.6%$155.16B$16.75B76.5553,000Upcoming EarningsBDXBecton, Dickinson and Company4.8181 of 5 stars$176.73+0.4%$219.22+24.0%-21.1%$50.65B$20.87B33.7374,000Positive NewsAnalyst RevisionEWEdwards Lifesciences4.3632 of 5 stars$78.66+0.8%$80.40+2.2%-14.1%$46.14B$5.44B11.2415,800Positive NewsUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies DXCM Competitors ISRG Competitors ABT Competitors JNJ Competitors NVST Competitors SYK Competitors TMO Competitors BSX Competitors BDX Competitors EW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MDT) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medtronic PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Medtronic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
